Apatinib in the Treatment of Metastatic Colorectal Cancer

Sponsor
Fudan University
Study ID
NCT03403452
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.

Study Details

This is an Exploratory Clinical Trial Study on Apatinib in the Treatment of Metastatic Colorectal Cancer Who Have Progressed after Standard Second Line Therapy.

Key Dates

Start date
Jan 1, 2018
Status verified
Jan 2018
Primary completion
Jun 30, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: arm for Apatinib
    500 mg,p.o.,qd

Primary Outcome Measure

PFS（progress free survival） [ Time Frame: From assignment of the first subject to 3 months later after the last participant is recruited ]

Central Contacts

Related Studies